Logo
 
USD 921.84  CAD 1208.93  EUR 863.80  AUD 1224.56  GBP 734.23 
 

Browse Categories

Search Options

Search terms:

Listing type:

All  Fixed Price  Auction

Product type:

All  Digital  Physical

Price range:

USD  to USD

Origin country:

Ships to:

Order by:

Active vendor:

Automatic fulfillment:

Multisig options:

Bulk discounts:

In stock:

Payment type:

Cryptocurrency:

Average vendor processing:

Vendor trust level:

to

Exchange Rates

Bitcoin (BTC)

United States Dollar (USD)
921.84
 
Canadian Dollar (CAD)
1,208.93
 
Euro (EUR)
863.80
 
Australian Dollar (AUD)
1,224.56
 
British Pound (GBP)
734.23
 
Deposits & Withdrawals
 

Monero (XMR)

United States Dollar (USD)
11.63
 
Canadian Dollar (CAD)
15.26
 
Euro (EUR)
10.90
 
Australian Dollar (AUD)
15.46
 
British Pound (GBP)
9.27
 
Deposits & Withdrawals
 

The above rates are updated every 10 minutes and taken using a weighted average of major exchange platforms.

 

DILAUDID 16mg Extended Release $25 each X 20 Pills HYDROMORPHONE

DILAUDID 16mg Extended Release AKA HYDROMORPHONE. Take one pill a day (recommended use) PRICE: $25 QTY: 20 PILLS MFG: MALLINKCRODT (EXALGO) or WATSON (SEEN IN LISTING PHOTO) Description Yellow tablet Generic Name Hydromorphone HCl extended-release tablets, CII Dosage Strength 16 mg Identification Code yellow, round tablet printed with “EXH 16” on one side EXALGO (hydromorphone HCI...

Sold by TEAMTEXAS - 12 sold since May 25, 2016  Vendor Level 9 Trust Level 8

 
Features
 
Product class
Physical package
 
Quantity left
6 items
 
Ends in
Never
 
 
Features
 
Origin country
United States
 
Ships to
United States
 
Payment
FE Listing 100%
 
 

Purchase price: USD 500.00

Qty:  
0.5424 BTC / 42.9923 XMR

 

Product Description

DILAUDID 16mg Extended Release AKA HYDROMORPHONE. Take one pill a day (recommended use)

PRICE: $25
QTY: 20 PILLS
MFG: MALLINKCRODT (EXALGO) or WATSON (SEEN IN LISTING PHOTO)
Description Yellow tablet
Generic Name Hydromorphone HCl extended-release tablets, CII
Dosage Strength 16 mg
Identification Code yellow, round tablet printed with “EXH 16” on one side

EXALGO (hydromorphone HCI) extended-release tablets (CII) is indicated for the management of pain in opioid-tolerant patients severe enough to require daily, around-the clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid.

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve EXALGO for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. EXALGO is not indicated as an as-needed (prn) analgesic.
IMPORTANT RISK INFORMATION

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; and NEONATAL OPIOID WITHDRAWAL SYNDROME

Addiction, Abuse, and Misuse
EXALGO exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing EXALGO, and monitor all patients regularly for the development of these behaviors or conditions

Life-threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of EXALGO. Monitor for respiratory depression, especially during initiation of EXALGO or following a dose increase. Instruct patients to swallow EXALGO tablets whole; crushing, chewing, or dissolving EXALGO tablets can cause rapid release and absorption of a potentially fatal dose of hydromorphone.

Accidental Exposure
Accidental ingestion of even one dose of EXALGO, especially in children, can result in a fatal overdose of hydromorphone.

Neonatal Opioid Withdrawal Syndrome
Prolonged use of EXALGO during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

CONTRAINDICATIONS

EXALGO is contraindicated in:
Opioid non-tolerant patients. Fatal respiratory depression could occur in patients who are not opioid tolerant.
Patients with significant respiratory depression
Patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Patients with known or suspected paralytic ileus
Patients who have had surgical procedures and/or underlying disease resulting in narrowing of the gastrointestinal tract, or have “blind loops” of the gastrointestinal tract or gastrointestinal obstruction
Patients with hypersensitivity (e.g., anaphylaxis) to hydromorphone or sulfite-containing medications

WARNINGS AND PRECAUTIONS

EXALGO contains hydromorphone, a Schedule II controlled substance. As an opioid, EXALGO exposes users to the risks of addiction, abuse, and misuse. As modified-release products such as EXALGO deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of hydromorphone present. With intravenous abuse, the tablet excipients, especially polyethylene oxide, can be expected to result in necrosis and inflammation of cardiac tissues. In addition, parenteral drug abuse is commonly associated with transmission of infectious disease such as hepatitis and HIV.
While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of EXALGO, the risk is greatest during the initiation of therapy or following a dose increase. Overestimating the EXALGO dose when converting patients from another opioid product can result in fatal overdose with the first dose. Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients. In patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory d

hydromorphone painm killers oxycodone norco dilaudid pain vicodin